Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15. Albireo executives taking part will include Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer. The team will participate in a fireside chat on April 13 at 9:30 a.m. ET, which will be available on-demand on the Albireo Media & Investors page at ir.albireopharma.com, as well as hosting meeting with investors throughout the conference.

Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference

– Dosed first patients in Phase 1 study with new product candidate A3907 –

Albireo Announces First Patients Dosed in Two New Studies

– Calls to unite global communities affected by rare diseases –

Albireo Spotlights Global Patient Communities on Rare Disease Day

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2020 Results - Earnings Call Transcript

– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –

Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update

BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference March 1-4, 2021. Ron Cooper, President and Chief Executive Officer of Albireo, will take part in the New Drug Launches Panel on Wednesday, March 3, 2021 at 10:20am ET. Members of the management team will also host meetings with investors on March 2.

Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences

Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET

Albireo to Report Q4 and Year-End 2020 Financial Results on February 25

– Company outlining large global rare cholestatic liver disease opportunity –

Albireo Presents Odevixibat Commercialization Road to $1 Billion

Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) is expected in the second half of 2021.

Albireo Pharma: De-Risked Small-Cap Biotech Ready For Commercialization

Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases

Albireo Recognizes International Alagille Syndrome Awareness Day 2021

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST.

Albireo to Host Virtual Investor Commercial Day 2021

- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -

Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC

- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -

New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease

- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -

Albireo Reports Q3 2020 Financial Results and Provides Business Update

- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases-

Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting

Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases

Albireo Recognizes PFIC Awareness Day 2020

BOSTON, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $40.00 per share. Albireo’s gross proceeds from this offering are expected to be $160 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Albireo. The offering is expected to close on or about September 14, 2020, subject to satisfaction of customary closing conditions.

Albireo Prices Public Offering of 4,000,000 Shares of Common Stock

BOSTON, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. All of the shares in the offering will be sold by Albireo. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock

Albireo Pharma (ALBO) is in the news Tuesday after positive results from a recent clinical trial sent ALBO stock soaring higher.
The post Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today appeared first on InvestorPlace.

Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today

The company reported positive data from a clinical trial.

Why Albireo Pharma Stock Is Skyrocketing Today

-Highly statistically significant reductions in both pruritus and serum bile acids-

Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC

— Conference call and webcast to be held at 8:30 a.m. EDT — — Conference call and webcast to be held at 8:30 a.m. EDT —

Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020

Investors need to pay close attention to Albireo Pharma (ALBO) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Albireo Pharma (ALBO) Stock?

Albireo (ALBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Albireo (ALBO) Looks Good: Stock Adds 5.1% in Session

Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.

News for Albireo Pharma Stock (ALBO)